These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28829799)

  • 1. Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways.
    Chen YJ; Wang WH; Wu WY; Hsu CC; Wei LR; Wang SF; Hsu YW; Liaw CC; Tsai WC
    PLoS One; 2017; 12(8):e0183368. PubMed ID: 28829799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.
    Henderson SE; Ding LY; Mo X; Bekaii-Saab T; Kulp SK; Chen CS; Huang PH
    Neoplasia; 2016 Dec; 18(12):765-774. PubMed ID: 27889645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
    Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
    Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer.
    Zhao B; He T
    Oncol Rep; 2015 Jan; 33(1):304-10. PubMed ID: 25384499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition.
    Zhang M; Pan Y; Dorfman RG; Chen Z; Liu F; Zhou Q; Huang S; Zhang J; Yang D; Liu J
    Oncotarget; 2016 Apr; 7(16):22285-94. PubMed ID: 26993777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells.
    Sato N; Ohta T; Kitagawa H; Kayahara M; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
    Int J Oncol; 2004 Mar; 24(3):679-85. PubMed ID: 14767553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
    Duo J; Ma Y; Wang G; Han X; Zhang C
    DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition.
    Wei D; Lu T; Ma D; Yu K; Zhang T; Xiong J; Wang W; Zhang Z; Fang Q; Wang J
    Life Sci; 2018 Oct; 211():224-237. PubMed ID: 30248347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone acetyltransferase inhibitor II induces apoptosis in glioma cell lines via the p53 signaling pathway.
    Xu LX; Li ZH; Tao YF; Li RH; Fang F; Zhao H; Li G; Li YH; Wang J; Feng X; Pan J
    J Exp Clin Cancer Res; 2014 Dec; 33(1):108. PubMed ID: 25523932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OBP‑801, a novel histone deacetylase inhibitor, induces M‑phase arrest and apoptosis in rhabdomyosarcoma cells.
    Tomoyasu C; Kikuchi K; Kaneda D; Yagyu S; Miyachi M; Tsuchiya K; Iehara T; Sakai T; Hosoi H
    Oncol Rep; 2019 Jan; 41(1):643-649. PubMed ID: 30365145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595.
    Minjie S; Defei H; Zhimin H; Weiding W; Yuhua Z
    Tumour Biol; 2015 Nov; 36(11):9015-22. PubMed ID: 26084607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
    Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
    Zhu Y; Yuan T; Zhang Y; Shi J; Bai L; Duan X; Tong R; Zhong L
    Drug Des Devel Ther; 2019; 13():4321-4330. PubMed ID: 31908417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.
    Gravina GL; Marampon F; Giusti I; Carosa E; Di Sante S; Ricevuto E; Dolo V; Tombolini V; Jannini EA; Festuccia C
    Int J Oncol; 2012 Mar; 40(3):711-20. PubMed ID: 22134754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel HDAC inhibitor AR-42-induced anti-colon cancer cell activity is associated with ceramide production.
    Xu W; Xu B; Yao Y; Yu X; Shen J
    Biochem Biophys Res Commun; 2015 Aug; 463(4):545-50. PubMed ID: 26026677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bufalin inhibits pancreatic cancer by inducing cell cycle arrest via the c-Myc/NF-κB pathway.
    Liu X; Xiao XY; Shou QY; Yan JF; Chen L; Fu HY; Wang JC
    J Ethnopharmacol; 2016 Dec; 193():538-545. PubMed ID: 27686271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling.
    Chen L; Feng D; Qian Y; Cheng X; Song H; Qian Y; Zhang X; Wu Y; Lv H; Liu Q; Cheng G; Yang B; Gu M
    Phytomedicine; 2021 May; 85():153537. PubMed ID: 33744595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
    Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
    Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models.
    Shieh JM; Wei TT; Tang YA; Huang SM; Wen WL; Chen MY; Cheng HC; Salunke SB; Chen CS; Lin P; Chen CT; Wang YC
    PLoS One; 2012; 7(1):e30240. PubMed ID: 22279574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.